21 Recruiting Chronic Lymphocytic Leukemia Phase 3 Clinical Trials
Active phase 3 studies for chronic lymphocytic leukemia enrolling across the USA. Verify eligibility and contact site coordinators.
All Chronic Lymphocytic Leukemia studiesPhase 3 Studies for Chronic Lymphocytic Leukemia
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
📍 Research Site — Chandler, Arizona
View Study & Checklist ➔Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
📍 Research Site — Phoenix, Arizona
View Study & Checklist ➔Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
📍 Research Site — Los Angeles, California
View Study & Checklist ➔Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 Southern Cancer Center, P.C. — Daphne, Alabama
View Study & Checklist ➔Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
📍 Research Site — Goodyear, Arizona
View Study & Checklist ➔A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
📍 Ironwood Physicians, Ironwood Cancer and Research Centers — Chandler, Arizona
View Study & Checklist ➔Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 California Research Institute — Los Angeles, California
View Study & Checklist ➔An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
📍 University of Arizona Cancer Center - Tucson /ID# 210548 — Tucson, Arizona
View Study & Checklist ➔A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
📍 Highlands Oncology Group ( Site 5205) — Springdale, Arkansas
View Study & Checklist ➔A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
📍 Augusta University — Augusta, Georgia
View Study & Checklist ➔Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
📍 Cedars-Sinai Medical Center — Los Angeles, California
View Study & Checklist ➔A Long-term Extension Study of PCI-32765 (Ibrutinib)
📍 City of Hope Cancer Center — Duarte, California
View Study & Checklist ➔A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
📍 Arizona Oncology - Tucson - Rudasill /ID# 267552 — Tucson, Arizona
View Study & Checklist ➔A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
📍 USA Mitchell Cancer Institute ( Site 0014) — Mobile, Alabama
View Study & Checklist ➔A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
📍 Uci Health Laguna Hills — Laguna Hills, California
View Study & Checklist ➔A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
📍 City of Hope National Medical Center — Duarte, California
View Study & Checklist ➔Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 Pacific Cancer Medical Center, Inc — Anaheim, California
View Study & Checklist ➔A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
📍 University of Alabama At Birmingham Hospital — Birmingham, Alabama
View Study & Checklist ➔